Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trialMathias Rummel, Wolfram Brugger, N. Niederle et al.|The Lancet|2013Cited by 1.5k
Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trialChristoph Röllig, Gerhard Ehninger, Hubert Serve et al.|The Lancet Oncology|2015Cited by 402
Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent lymphomas: Nine-year updated results from the StiL NHL1 study.Mathias Rummel, Wolfram Brugger, Georg Maschmeyer et al.|Journal of Clinical Oncology|2017Cited by 83
Sorafenib or placebo in patients with newly diagnosed acute myeloid leukaemia: long-term follow-up of the randomized controlled SORAML trialChristoph Röllig, Hubert Serve, Richard Noppeney et al.|Leukemia|2021Cited by 58
Phase <scp>II</scp> study of bortezomib, cyclophosphamide and dexamethasone as induction therapy in multiple myeloma: <scp>DSMM XI</scp> trialHermann Einsele, Stefan Knop, Monika Engelhardt et al.|British Journal of Haematology|2017Cited by 30